ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일
Multiple solid tumors · PD-1
Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1
HER2+ breast cancer, HER2+ gastric/GEJ adenocarcinoma · HER2
NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1
NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1
Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA · TNF-α
Multiple myeloma · CD38
Type 2 diabetes, chronic weight management, CV risk reduction (T2D) · GLP-1 receptor
Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis · IL-4Rα
Type 2 diabetes, chronic weight management · GLP-1 / GIP receptor
Wet AMD, DME, RVO, diabetic retinopathy · VEGF-A / VEGF-B / PIGF
Metastatic triple-negative breast cancer, pretreated HR+/HER2− breast cancer · TROP2
HER2+ breast cancer, HER2-low, gastric · HER2
RA, PsA, AS, plaque psoriasis, JIA · TNF (decoy receptor)
Wet AMD, DME, RVO, myopic CNV · VEGF-A
Psoriasis, PsA, AS, nr-axSpA, HS · IL-17A
Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and c… · PD-1
Locally advanced or metastatic urothelial carcinoma · Nectin-4
Psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis · IL-12 / IL-23 (p40)
Hodgkin's Disease · Hodgkin Disease
1 / 121 pages
구조모아 (StructureMoa)항암 chemical structure spider web
KRMediMoa한의학·한약재 임상·근거 데이터
다음 갱신 D-5 · 마지막 9월 2일 · 방문 1,154 / 70,988